Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
April 11, 2023
In this blog, we make the case that WHO should shift away from disease siloes and reorganize to streamline the cross-cutting functions that it delivers to member countries. The WHO has an opportunity to streamline its functions along the continuum of science practice—from registering clinical trials...
Blog Post
February 23, 2021
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the be...
Jul
9
2020
3:30—5:00 PM ET
July 07, 2020
The US International Development Finance Corporation, better known as DFC, recently launched the first iteration of its Impact Quotient (IQ), a new tool the agency will use to assess the development impact of prospective projects on growth, inclusion, and innovation. Designed to be integrated throug...
Blog Post
March 22, 2017
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, howe...
Blog Post
December 20, 2016
In 2016 on the CGD Podcast, we have discussed some of development's biggest questions: How do we pay for development? How do we measure the sustainable development goals (SDGs)? What should we do about refugees and migrants? And is there life yet in the notion of globalism? The links to all the ...
BRIEFS
June 04, 2012
Decisions about which type of patients receive what interventions, when, and at what cost often result from ad hoc, nontransparent processes driven more by inertia and interest groups than by science, ethics, and the public interest. Reallocating a portion of public and donor monies toward the most ...
REPORTS
June 04, 2012
Decisions about which type of patients receive what interventions, when, and at what cost often result from ad hoc, nontransparent processes driven more by inertia and interest groups than by science, ethics, and the public interest. Reallocating a portion of public and donor monies toward the most ...